Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Travere Therapeutics	Amneal Pharmaceuticals	Olema Pharmaceuticals	Zealand Pharma A/S	Ironwood Pharmaceuticals
Symbol	NASDAQ:TVTX	NYSE:AMRX	NASDAQ:OLMA	NASDAQ:ZEAL	NASDAQ:IRWD
Price Information
Current Price	$24.95	$5.89	$36.14	$32.56	$10.61
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.2	1.8	1.6	1.2	1.6
Analysis Score	3.5	2.4	3.5	3.5	1.1
Community Score	2.6	2.2	4.3	2.5	2.2
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.0	0.0	1.7
Earnings & Valuation Score	0.0	4.4	0.0	0.0	3.1
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$44.33	$7.00	$60.67	$43.00	$11.40
% Upside from Price Target	77.69% upside	18.85% upside	67.87% upside	32.06% upside	7.45% upside
Trade Information
Market Cap	$1.51 billion	$1.77 billion	$1.45 billion	$1.41 billion	$1.71 billion
Beta	0.77	1.27	N/A	1.19	1.46
Average Volume	598,872	1,990,179	149,105	14,216	2,143,958
Sales & Book Value
Annual Revenue	$175.34 million	$1.63 billion	N/A	$6.20 million	$428.41 million
Price / Sales	8.60	1.09	N/A	227.92	3.99
Cashflow	N/A	$1.37 per share	N/A	N/A	$0.54 per share
Price / Cash	N/A	4.29	N/A	N/A	19.49
Book Value	$5.15 per share	$1.16 per share	N/A	$5.85 per share	($0.59) per share
Price / Book	4.84	5.08	N/A	5.57	-17.98
Profitability
Net Income	$-146,430,000.00	$-361,920,000.00	N/A	$-85,670,000.00	$21.50 million
EPS	($3.46)	$0.27	N/A	($2.54)	$0.55
Trailing P/E Ratio	N/A	14.37	0.00	N/A	15.38
Forward P/E Ratio	N/A	8.92	N/A	N/A	9.23
P/E Growth	N/A	0.29	N/A	N/A	N/A
Net Margins	-40.24%	3.30%	N/A	-214.31%	27.77%
Return on Equity (ROE)	-29.27%	42.02%	N/A	-38.34%	-240.80%
Return on Assets (ROA)	-12.25%	3.82%	N/A	-30.40%	27.05%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.71%	8.20%	N/A	N/A	71.91%
Current Ratio	6.60%	2.31%	N/A	6.76%	13.17%
Quick Ratio	6.50%	1.60%	N/A	6.51%	13.17%
Ownership Information
Institutional Ownership Percentage	N/A	33.49%	N/A	4.32%	N/A
Insider Ownership Percentage	4.63%	26.32%	N/A	N/A	2.40%
Miscellaneous
Employees	N/A	6,000	36	329	232
Shares Outstanding	60.44 million	299.82 million	40.17 million	43.40 million	160.96 million
Next Earnings Date	5/10/2021 (Estimated)	5/7/2021 (Confirmed)	6/16/2021 (Estimated)	5/13/2021 (Estimated)	5/5/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	If You Like EPS Growth Then Check Out Ironwood Pharmaceuticals (NASDAQ:IRWD) Before It's Too Late finance.yahoo.com - April 15 at 2:43 PM
	Ironwood Pharmaceuticals (IRWD) Shares Cross Below 200 DMA nasdaq.com - April 7 at 6:24 PM
	First Week of November 19th Options Trading For Ironwood Pharmaceuticals (IRWD) nasdaq.com - March 19 at 3:28 PM
	Ironwood (IRWD) Up 20.4% Since Last Earnings Report: Can It Continue? finance.yahoo.com - March 19 at 3:28 PM
	IRWD Makes Bullish Cross Above Critical Moving Average nasdaq.com - March 8 at 12:53 PM
	Edward Owens Is The Independent Director of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) And They Just Picked Up 5.9% More Shares finance.yahoo.com - March 1 at 1:27 PM
	Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences finance.yahoo.com - February 19 at 5:31 PM
	Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q4 2020 Results - Earnings Call Transcript seekingalpha.com - February 19 at 12:30 PM
	Ironwood Pharmaceuticals is Now Oversold (IRWD) nasdaq.com - February 18 at 8:22 PM
	Ironwood Pharmaceuticals (IRWD) Surpasses Q4 Earnings and Revenue Estimates msn.com - February 17 at 1:30 PM
	Recap: Ironwood Pharmaceuticals Q4 Earnings finance.yahoo.com - February 17 at 1:30 PM
	Ironwood Pharmaceuticals Inc (IRWD) Q4 2020 Earnings Call Transcript finance.yahoo.com - February 17 at 1:30 PM
	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year us.acrofan.com - February 17 at 8:30 AM
	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance finance.yahoo.com - February 17 at 8:30 AM
	Ironwood Pharmaceuticals Q4 2020 Earnings Preview seekingalpha.com - February 16 at 12:40 PM
	Ironwood CEO Steps Down Months After Clinical Trial Failure, Names Thomas McCourt As Interim Chief Executive feeds.benzinga.com - February 9 at 5:29 AM
	Ironwood Pharmaceuticals Announces CEO Transition finance.yahoo.com - February 8 at 6:04 PM
	Investors Aren't Entirely Convinced About Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Earnings finance.yahoo.com - February 8 at 1:03 PM
	Ironwood Pharmaceuticals fool.com - February 6 at 6:25 PM
	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call finance.yahoo.com - February 3 at 8:01 PM
	IRWD Crosses Below Key Moving Average Level nasdaq.com - January 23 at 6:44 PM
	Interesting IRWD Put And Call Options For March 19th nasdaq.com - January 15 at 12:47 PM
	Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 5 at 8:10 AM
	Ironwood (IRWD) Up 19.7% Since Last Earnings Report: Can It Continue? finance.yahoo.com - December 5 at 4:33 PM
	Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors finance.yahoo.com - December 3 at 1:19 PM

Date	Company	Brokerage	Action
4/12/2021	Travere Therapeutics	Wedbush	Lower Price Target
3/3/2021	Travere Therapeutics	SVB Leerink	Reiterated Rating
3/2/2021	Travere Therapeutics	BMO Capital Markets	Lower Price Target
2/3/2021	Travere Therapeutics	Canaccord Genuity	Boost Price Target
11/23/2020	Travere Therapeutics	Evercore ISI	Initiated Coverage
4/14/2021	Amneal Pharmaceuticals	Guggenheim	Boost Price Target
3/19/2021	Amneal Pharmaceuticals	Piper Sandler	Boost Price Target
3/15/2021	Amneal Pharmaceuticals	The Goldman Sachs Group	Upgrade
3/1/2021	Amneal Pharmaceuticals	Barclays	Boost Price Target
5/13/2020	Amneal Pharmaceuticals	SunTrust Banks	Boost Price Target
4/16/2020	Amneal Pharmaceuticals	Royal Bank of Canada	Reiterated Rating
4/2/2020	Amneal Pharmaceuticals	Morgan Stanley	Lower Price Target
12/13/2019	Amneal Pharmaceuticals	Piper Jaffray Companies	Boost Price Target
12/12/2019	Amneal Pharmaceuticals	BTIG Research	Boost Price Target
12/12/2019	Amneal Pharmaceuticals	Raymond James	Downgrade
11/12/2019	Amneal Pharmaceuticals	JPMorgan Chase & Co.	Downgrade
12/14/2020	Olema Pharmaceuticals	Jefferies Financial Group	Initiated Coverage
12/14/2020	Olema Pharmaceuticals	Cowen	Initiated Coverage
8/13/2020	Zealand Pharma A/S	Needham & Company LLC	Initiated Coverage
11/6/2020	Ironwood Pharmaceuticals	Credit Suisse Group	Boost Price Target
9/30/2020	Ironwood Pharmaceuticals	Wells Fargo & Company	Downgrade
8/3/2020	Ironwood Pharmaceuticals	Northland Securities	Reiterated Rating
5/11/2020	Ironwood Pharmaceuticals	HC Wainwright	Lower Price Target
5/2/2019	Ironwood Pharmaceuticals	Mizuho	Set Price Target

(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources